VTGN News and Press, VistaGen Therapeutics Inc. From 08/09/22

VistaGen Therapeutics, Inc . (NASDAQ: VTGN) a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and web...

Buying Penny Stocks on July 26th? Here’s What You Need to Know If you’re looking for penny stocks to buy on July 26th, there are hundreds of options to choose from. And in the last few months, we’ve seen a major amount of movement across the board with both penny ...

Baird has downgraded Vistagen ( NASDAQ: VTGN ) after a phase 3 trial for anxiety medication PH94B failed to meet its primary endpoint . The firm removed its $9 price target. The stock closed at $0.15 Friday following the news, dropping 86% that day. Analyst Bri...

3 Things to Know for Buying Penny Stocks Next Month If you’re thinking about trading penny stocks in August, there is a lot for investors to know. For starters, the stock market is volatile and ever-changing, so it’s important to do your research before investing. Secondly...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Peshkova Pagaya Technologies (NASDAQ: PGY ) stock is rocketing higher on Friday despite a lack of news from the financial tech company today. While there’s no news today, Pagaya...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com VistaGen Therapeutics (NASDAQ: VTGN ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study . Th...

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) announced topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the treatment of anxiety in adults with social anxiety disorder.  PH94B did not reach its primary endpoint.  “The demand for new treatment ...

Gainers: Hanger HNGR +25% . Community Health Systems ( CYH ) +19% . HCA Healthcare HCA +14% . LumiraDx ( LMDX ) +11% .  Tenet Healthcare ( THC ) +9% . Losers: VistaGen Therapeutics VTGN -84% . Addex Therapeutics ADXN ...

Clinical-stage biotech VistaGen Therapeutics ( NASDAQ: VTGN ) announced on Friday that the company’s PALISADE-1 Phase 3 clinical trial for anxiety therapy PH94B did not meet the primary endpoint. After a brief trading halt, VistaGen ( VTGN ) shares crashed 80...

Clinical-stage biotech VistaGen Therapeutics ( NASDAQ: VTGN ) announced on Friday that the company’s PALISADE-1 Phase 3 clinical trial for anxiety therapy PH94B did not meet the primary endpoint. The multi-center, placebo-controlled study was designed to evaluate PH...